Cardium Therapeutics Inc. Comm (CRXM) 0.4128 $CRXM
Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
PR Newswire - Wed Aug 13, 8:00AM CDT
Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional angioplasty, stent placement or bypass surgery.
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx(R) Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention
Business Wire - Tue Jun 24, 8:01AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(R) Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's Chief Executive Officer and Cardium Therapeutics' co-founder, at 4:30 pm June 24 in the Mission Beach room.
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention
PR Newswire - Tue Jun 24, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx® Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's Chief Executive Officer and Cardium Therapeutics' co-founder, at 4:30 pm June 24 in the Mission Beach room.
Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
PR Newswire - Thu Jun 12, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), announced today that Cardium Therapeutics will announce interim results on the Generx® angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California. The presentation will be made by Cardium's chief executive officer Christopher Reinhard on June 24, 2014, and will also be made available through the Company's website on that day.
Cardium Becomes Taxus Cardium Pharmaceuticals Group In Connection With Strategic Collaboration And Funding With Shanxi Taxus Pharmaceuticals
PR Newswire - Mon Mar 17, 8:00AM CDT
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has changed its corporate name and business to Taxus Cardium Pharmaceuticals Group Inc. in connection with its strategic collaboration and funding arrangement concluded with China-based Shanxi Taxus Pharmaceuticals Co., Ltd.
Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development Of Advanced Regenerative Therapeutics
PR Newswire - Mon Mar 03, 8:00AM CST
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®, FDA-cleared advanced wound care product. The Company's name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration.
Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
PR Newswire - Mon Jan 27, 8:00AM CST
Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx® Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen® for wound healing and as a biologics delivery platform.
Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
PR Newswire - Wed Aug 13, 8:00AM CDT
Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional angioplasty, stent placement or bypass surgery.
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx(R) Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention
Business Wire - Tue Jun 24, 8:01AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(R) Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's Chief Executive Officer and Cardium Therapeutics' co-founder, at 4:30 pm June 24 in the Mission Beach room.
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention
PR Newswire - Tue Jun 24, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx® Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's Chief Executive Officer and Cardium Therapeutics' co-founder, at 4:30 pm June 24 in the Mission Beach room.
Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
PR Newswire - Thu Jun 12, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), announced today that Cardium Therapeutics will announce interim results on the Generx® angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California. The presentation will be made by Cardium's chief executive officer Christopher Reinhard on June 24, 2014, and will also be made available through the Company's website on that day.
Cardium Becomes Taxus Cardium Pharmaceuticals Group In Connection With Strategic Collaboration And Funding With Shanxi Taxus Pharmaceuticals
PR Newswire - Mon Mar 17, 8:00AM CDT
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has changed its corporate name and business to Taxus Cardium Pharmaceuticals Group Inc. in connection with its strategic collaboration and funding arrangement concluded with China-based Shanxi Taxus Pharmaceuticals Co., Ltd.
Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development Of Advanced Regenerative Therapeutics
PR Newswire - Mon Mar 03, 8:00AM CST
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®, FDA-cleared advanced wound care product. The Company's name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration.
Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
PR Newswire - Mon Jan 27, 8:00AM CST
Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx® Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen® for wound healing and as a biologics delivery platform.
